1. Volume 97, Pages 59-63 (December 2016)
Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer 
Qing-qing Luo, Vishnu Prasad Adhikari, Chun-xia Zhao, He Wu, Wei Dai, Xin Li, Yu-tuan Wu, Kai-nan Wu, Ling-quan Kong 
Medical Hypotheses 
Volume 97, Pages (December 2016)
DOI: /j.mehy
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Fig. 1
Prevalent mode of treating of HR+ HER2− MBC. CT mainly targets HR+ tumor ingredients while HR− cells keep progressing. For patients react poorly to ET, CT is applied. However, chemotherapy is less effective on HR+ cells. During this process, tumor burden evolves with time and hormone resistance is more likely to occur.
Medical Hypotheses  , 59-63DOI: ( /j.mehy )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Fig. 2
Chemohormonal therapy with concurrent use of fulvestrant and CT. With this modality, both HR+ and HR− portion of the tumor is covered, realizing double kill. Tumor burden is reduced over a short period of time and hormone resistance is less likely to occur.
Medical Hypotheses  , 59-63DOI: ( /j.mehy )
Copyright © 2016 Elsevier Ltd Terms and Conditions